Patents by Inventor Colin Dunstan

Colin Dunstan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biocompatible material and uses thereof
    Patent number: 9220806
    Abstract: The present invention relates to a biocompatible material and in particular to a two-phase or composite biocompatible ceramic material, wherein the first phase is a doped calcium zinc silicate and the second phase is a metal oxide. In an embodiment, the invention has been developed for use in tissue regeneration including bone tissue. In other embodiments, the invention has been developed as a coating to improve the long-term stability of prior art implantable medical devices.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: December 29, 2015
    Assignee: The University of Sydney
    Inventors: Hala Zreiqat, Seyed-Iman Roohani-Esfahani, Colin Dunstan, Jiao Jiao Li
  • OMEGA-3 ANALOGUES
    Publication number: 20150322001
    Abstract: The present invention relates to new fatty acid analogues and to their use in cancer therapy, including antimetastatic therapy.
    Type: Application
    Filed: November 21, 2013
    Publication date: November 12, 2015
    Inventors: Michael MURRAY, Tristan RAWLING, Colin DUNSTAN, Pei Hong CUI
  • Biocompatible material and uses thereof
    Patent number: 8765163
    Abstract: The present invention relates to a biocompatible ceramic material comprising Sr, Mg or Ba doped Hardystonite (Ca2ZnSi2O7), and a method for its synthetic preparation. The present invention also relates to an implantable medical device comprising biocompatible doped Hardystonite, and a method for its production. The present invention further relates to a method for improving the long term stability of an implantable medical device and an implantable drug delivery device comprising doped Hardystonite. Further, the present invention relates to the use of comprising biocompatible doped Hardystonite in the regeneration or resurfacing of tissue.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: July 1, 2014
    Assignee: The University of Sydney
    Inventors: Hala Zreiqat, Chengtie Wu, Colin Dunstan
  • BIOCOMPATIBLE MATERIAL AND USES THEREOF
    Publication number: 20140105940
    Abstract: The present invention relates to a biocompatible material and in particular to a two-phase or composite biocompatible ceramic material, wherein the first phase is a doped calcium zinc silicate and the second phase is a metal oxide. In an embodiment, the invention has been developed for use in tissue regeneration including bone tissue. In other embodiments, the invention has been developed as a coating to improve the long-term stability of prior art implantable medical devices.
    Type: Application
    Filed: June 1, 2012
    Publication date: April 17, 2014
    Applicant: The University of Sydney
    Inventors: Hala Zreiqat, Seyed-Iman Roohani-Esfahani, Colin Dunstan, Jiao Jiao Li
  • BIOCOMPATIBLE MATERIAL AND USES THEREOF
    Publication number: 20110111005
    Abstract: The present invention relates to a biocompatible ceramic material comprising Sr, Mg or Ba doped Hardystonite (Ca2ZnSi2O7), and a method for its synthetic preparation. The present invention also relates to an implantable medical device comprising biocompatible doped Hardystonite, and a method for its production. The present invention further relates to a method for improving the long term stability of an implantable medical device and an implantable drug delivery device comprising doped Hardystonite. Further, the present invention relates to the use of comprising biocompatible doped Hardystonite in the regeneration or resurfacing of tissue.
    Type: Application
    Filed: July 10, 2009
    Publication date: May 12, 2011
    Applicant: The University of Sydney
    Inventors: Hala Zreiqat, Chengtie Wu, Colin Dunstan
  • Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
    Publication number: 20060019887
    Abstract: The present invention relates to compositions and methods for the prevention and/or treatment of bone loss associated with cancer. More particularly, the invention relates to OPG compositions and methods for the prevention and/or treatment of bone loss comprising said compositions. The invention also relates to the use of OPG compositions for the treatment of multiple myeloma.
    Type: Application
    Filed: September 22, 2004
    Publication date: January 26, 2006
    Inventor: Colin Dunstan
  • Mice lacking expression of osteoprotegerin
    Patent number: 6087555
    Abstract: Disclosed is a mouse in which expression of the gene encoding Osteoprotegerin is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: July 11, 2000
    Assignee: Amgen Inc.
    Inventors: Colin Dunstan, Scott Simonet, Ildiko Sarosi